Article
Efficacy and safety of afatinib in Chinese patients with EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) previously responsive to first-generation tyrosine-kinase inhibitors (TKI) and chemotherapy: comparison with historical cohort using erlotinib.
BMC cancer - 24 Feb 2016
Lee Victor H F, Leung Dennis K C, Choy Tim-Shing, Lam Ka-On, Lam Pui-Mei, Leung To-Wai, Kwong Dora L W
Abstract excerpt
BACKGROUND: Afaitnib has shown anti-tumor activity against metastatic EGFR-mutated NSCLC after prior failure to first generation EGFR-TKI and chemotherapy. We prospectively evaluated the efficacy and safety of afatinib in Chinese patients who previously failed first-generation TKI and chemotherapy under a compassionate use program (CUP) and compared to the erlotinib cohort. METHODS: Patients who suffered from...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.